These findings proved that PERK is a promising target for alleviating GVHD while preserving the GVL effect, supporting clinical investigation to validate targeting of PERK as a potential therapeutic strategy in the control of GVHD and leukemia relapse. Here, EIF2AK3 is linked to graft versus host disease.